title: [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
abstract: OBJECTIVE
  As a multifunctional Th2-cytokine, interleukin-10 (IL-10)plays a major role in the immune response. It is well known that IL-10 is an immunosuppressive cytokine, and participates in the development and progression of various tumors. In this study, we investigated the relationship between the IL-10 level in the ascites of the patients with primary ovarian epithelial carcinoma (POEC) and immune defect in the peritoneal cavity.
  
  
  METHODS
  The IL-10 levels in serum and ascites of 32 patients with POEC, in culture supernatants of 4 different ovarian carcinoma cell lines and in serum of 10 patients with ovarian epithelial benign tumor and 10 health women (control) were measured by enzyme-linked immunosorbent assay (ELISA).
  
  
  RESULTS
  (1) IL-10 level in ascites was significantly higher than that in serum of patients with POEC, (159.78+/-51.20 ng/L vs 12.01+/-4.38 ng/L, P=0.000). IL-10 level in serum of the patients with POEC (12.01+/-4.38 ng/L) was significantly higher than that of the patients with benign tumor (3.79+/-2.40 ng/L, P=0.000) and control (4.45+/-2.69 ng/L, P=0.003). There was no significant difference of IL-10 level in serum between ovarian benign tumor and control (P=0.529). (2) IL-10 level in ascites of the patients with POEC was correlated with FIGO stage but not correlated with histological grade. (3) IL-10 was detectable in culture supernatants of 4 different ovarian cancer cell lines (3ao, SKOV3, CAOV3 and OVCAR).
  
  
  CONCLUSIONS
  High level of IL-10 in ascites of the patients with POEC is probably associated with immune defect in their peritoneal cavity, ovarian cancer cells may promote metastasis in peritoneal cavity by secreting IL-10.
authors.affiliation: Department of Gynecology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310006, PR China.
authors.forename: Jian-Wei
authors.initials: JW
authors.lastname: Zhou
authors.forename: Qi
authors.initials: Q
authors.lastname: Cheng
authors.forename: Xing
authors.initials: X
authors.lastname: Xie
authors.forename: Huai-Zeng
authors.initials: HZ
authors.lastname: Chen
authors.forename: Da-Feng
authors.initials: DF
authors.lastname: Ye
authors.forename: Wei-Guo
authors.initials: WG
authors.lastname: Lu
mesh_terms: D000328:Adult; D000368:Aged; D001202:Ascitic Fluid / Q000737:chemistry*; D045744:Cell Line, Tumor; D018282:Cystadenocarcinoma, Mucinous / Q000276:immunology / Q000473:pathology; D018284:Cystadenocarcinoma, Serous / Q000276:immunology / Q000473:pathology; D018291:Cystadenoma, Mucinous / Q000276:immunology / Q000473:pathology; D018293:Cystadenoma, Serous / Q000276:immunology / Q000473:pathology; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000378:metabolism*; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000473:pathology; D010537:Peritoneum / Q000276:immunology*
chemical_list: D016753:Interleukin-10